Imatinib mesylate (STI571) in patients with chronic myeloid leukemia in chronic phase previously submitted to autologous stem cell transplantation.

被引：0
|
作者：
Cervantes, F
Hernández-Boluda, JC
Odriozola, J
Camós, M
Villalón, L
Martínez-Climent, JA
del Campo, R
García-Conde, J
Montserrat, E
机构：
[1] IDIBAPS, Hosp Clin, Dept Hematol, Barcelona, Spain
[2] Hosp Clin, Dept Hematol & Oncol, Valencia, Spain
[3] Hosp Ramon y Cajal, Hematol Serv, E-28034 Madrid, Spain
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4818
引用
收藏
页码：318B / 318B
页数：1
相关论文
共 50 条
  • [1] Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
    Cervantes, F
    Hernández-Boluda, JC
    Odriozola, J
    Camós, M
    Villalón, L
    Martínez-Climent, JA
    Del Campo, R
    García-Conde, J
    Montserrat, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) : 500 - 504
  • [2] Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation
    Olavarria, E
    Craddock, C
    Dazzi, F
    Marin, D
    Marktel, S
    Apperley, JF
    Goldman, JM
    BLOOD, 2002, 99 (10) : 3861 - 3862
  • [3] Imatinib mesylate (STI571) in CML patients after autologous peripheral blood stem cell transplantation
    Mahmoud, HK
    El-Emary, M
    Nazier, AA
    El-Haddad, A
    Fahmy, OA
    El-Sayed, N
    AbdMooti, M
    Nasser, A
    Sobhy, A
    El-Nahass, Y
    BONE MARROW TRANSPLANTATION, 2006, 37 : S231 - S231
  • [4] Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: Rapid response to imatinib mesylate (STI571)
    Imashuku, S
    Morimoto, A
    Kuriyama, K
    Kano, G
    Hibi, S
    Todo, S
    MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 41 (02): : 159 - +
  • [5] Stem cell collection in chronic myeloid leukemia patients with cytogenetic response to imatinib mesylate (STI 571, gleevec)
    Hardan, I
    Lennard, A
    Nagler, A
    Shimoni, A
    Sareli, R
    Boque, C
    Canzio, M
    Olavarria, E
    Niederwieser, D
    BONE MARROW TRANSPLANTATION, 2003, 31 : S62 - S62
  • [6] Rapid improvement of donor chimerism after imatinib mesylate (Sti571) treatment in the relapse of chronic myeloid leukemia after allogeneic stem cell transplantation
    Beneitez, D
    Ferrà, C
    Gallardo, D
    Berlanga, JJ
    Hermosilla, M
    Grañena, A
    BONE MARROW TRANSPLANTATION, 2003, 31 : S164 - S164
  • [7] Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
    Kvasnicka, HM
    Thiele, J
    Staib, P
    Schmitt-Graeff, A
    Griesshammer, M
    Klose, J
    Engels, K
    Kriener, S
    BLOOD, 2004, 103 (09) : 3549 - 3551
  • [8] Glivec (STI571) in the treatment of patients with chronic myeloid leukemia (CML) relapsing in accelerated or blastic phase after allogenic stem cell transplantation.
    Wassmann, B
    Pfeifer, H
    Scheuring, U
    Brueck, P
    Binckebank, A
    Atta, J
    Martin, H
    Gschaidmeier, H
    Thiede, C
    Bornhauser, M
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2001, 98 (11) : 140A - 140A
  • [9] Imatinib mesylate therapy in patients with chronic myeloid leukaemia previously treated with autologous stem cell transplantation
    Cortés, M
    Sureda, A
    Martino, R
    Aventin, A
    Nomdedeu, J
    Briones, J
    Valcárcel, D
    Brunet, S
    Sierra, J
    BONE MARROW TRANSPLANTATION, 2004, 33 : S151 - S151
  • [10] Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia
    Legros, L
    Bourcier, C
    Jacquel, A
    Mahon, FX
    Cassuto, JP
    Auberger, P
    Pagès, G
    BLOOD, 2004, 104 (02) : 495 - 501
12345